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Abstract
Background: Several epidemiologic studies have shown a possible association between thyroid function and 
cognitive decline. Our aim was to evaluate the association of subclinical hyperthyroidism and dementia in a population 
sample of older people
Methods: A cross-sectional study - São Paulo Ageing & Health Study (SPAH) - in a population sample of low-income 
elderly people ≥ 65 years-old to evaluate presence of subclinical thyroid disease as a risk factor for dementia. Thyroid 
function was assessed using thyrotropic hormone and free-thyroxine as well as routine use of thyroid hormones or 
antithyroid medications. Cases of dementia were assessed using a harmonized one-phase dementia diagnostic 
procedure by the "10/66 Dementia Research Group" including Alzheimer's disease and vascular dementia. Logistic 
regression models were used to test a possible association between subclinical hyperthyroidism and dementia.
Results and discussion: Prevalence of dementia and of subclinical hyperthyroidism were respectively of 4.4% and 
3.0%. After age adjustment, we found an association of subclinical hyperthyroidism and any type of dementia and 
vascular dementia (Odds Ratio, 4.1, 95% Confidence Interval [95% CI] 1.3-13.1, and 5.3 95% CI, 1.1-26.4; respectively). 
Analyzing data by gender, we found an association of subclinical hyperthyroidism with dementia and Alzheimer's 
disease only for men (OR, 8.0; 95% CI, 1.5-43.4; OR, 12.4; 95% CI, 1.2-128.4; respectively). No women with subclinical 
hypothyroidism presented Alzheimer's disease in the sample.
Conclusion: The results suggest a consistent association among people with subclinical hyperthyroidism and 
dementia.
Background
Thyroid disease and dementia are relatively common in
elderly people. However, the diagnosis is difficult as
symptoms can be vague and clinical presentation is con-
founded by the ageing process. Due to the close associa-
tion between thyroid function and cognitive
performance, the hypothesis thyroid dysfunction may be
a risk factor for cognitive impairment has been investi-
gated with conflicting results [1-10]. The Leiden-85 study
did not show any association between levels of thyroid
stimulating hormone (TSH) and free thyroxine (FT4) [1]
with cognitive impairment. However, the Women's
Health and Aging Study reported cognitive decline in
women with low levels of total thyroxine (T4) over a three
year period, although this trend was within the normal
range for women [2].
In contrast to previous data, the Rotterdam Study
determined that subclinical hyperthyroidism increased
the risk of dementia and Alzheimer's disease three fold at
follow-up in 1,893 participants [4], and the Kungsholmen
Project identified an association between declining levels
of TSH and a six year increase of memory deficit at fol-
low-up [5]. The Rotterdam Scan Study did not show any
association between TSH and thyroid hormone levels and
the risk of dementia or Alzheimer's disease; however,
nondemented subjects with higher FT4 levels exhibited
greater hippocampal and amygdalar atrophy on magnetic
resonance imaging [6]. The Honolulu-Asia Aging Study
determined that higher total and FT4 levels were consis-
tently associated with dementia, Alzheimer's disease, and
neuropathology [7]. * Correspondence: isabensenor@hu.usp.br
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Recently, two prospective studies evaluated the rela-
tionship between thyroid function and risk of dementia
and found an association in both directions. Hogevorst et
al. found a positive association between hypothyroidism
and cognitive impairment in a sample of elderly patients,
as well as a positive association among participants with
high-normal FT4 levels and cognitive impairment after
two year follow-up [8]. The Framingham Study disclosed
a positive association between women with serum thy-
rotropin in the lowest (< 1.0 mIU/L) or highest (> 2.1
mIU/L) tertiles of serum thyrotropin concentration and
an increased risk of Alzheimer's disease, although no
relationship was found between thyroid function and
Alzheimer's disease in men [9]. Both studies suggest that
low and high-normal TSH/FT4 levels can be associated
with an increased risk of cognitive impairment or even
Alzheimer's disease.
There have been few studies in Brazil concerning the
prevalence of dementia, and no previous data has been
gathered regarding the prevalence of thyroid dysfunction
in population-based samples of older people. The present
study is the first cross-sectional population-based study
to explore the relationship of thyroid function and
dementia, Alzheimer's disease, and vascular dementia in
low-income, elderly people in the city of São Paulo, Bra-
zil.
Methods
A cross-sectional one-phase population-based study was
carried out with all residents aged 65 years-old or older
living in a economically deprived area of São Paulo, Bra-
zil, to evaluate prevalence of dementia as part of a collab-
orative program developed by the 10/66 Dementia
Research Group. Participants were those enrolled in the
baseline assessment of the Sao Paulo Ageing & Health
Study (SPAH) whose methodology can be assessed else-
where [10,11]. The study was approved by the Institu-
tional Review Board and all participants signed an
informed consent.
Sample
The baseline assessment of the SPAH was carried out
with all people aged 65 years or older, residents in 66 pre-
d e t e r m i n e d  c e n s u s  s e c t o r s  ( c a t c h m e n t  a r e a s )  i n  t h e
neighborhood of Butantan located in the Western side of
the city of São Paulo. Study participants lived in shanty-
towns or households covered by primary care units from
the Family Health Program, with the lowest family
income in the area. A total of 2,072 persons (91.4% of
those invited) were recruited through systematic door
knocking and were included in the SPAH. As the investi-
gation of thyroid disorders started after the baseline
assessment of the SPAH was underway, 699 [33.7%] par-
ticipants included in the SPAH with no data about thy-
roid function were excluded from the present study.
There was no difference regarding age, sex, socio-demo-
graphic, and anthropometric variables between the par-
ticipants included in the thyroid function study as
compared to the 699 non-participants. We have also
excluded from the analysis 97 patients with clinical thy-
roid dysfunction or using medication for thyroid disor-
ders, totaling 1,276 participants.
Procedures
The study was conducted over a two-year period, from
May 2003 to April 2005. All those aged at 65 years or over
living in the study catchment area who accepted to par-
ticipate in the study were interviewed. This meant that in
households with two or more elderly people, all of them
were invited to participate. All participants were assessed
for socioeconomic characteristics.
Venous blood sample was obtained after an overnight
fast. The serum obtained after centrifugation was used
for hormone and biochemistry measurements. Thyroid
stimulating hormone (TSH) concentration was measured
by immunometric assay (kit AutoDelfiahTSH) and free-
thyroxin (FT4) concentration was also determined using
an immunometric assay (kit AutoDelfia T4). Anti-thyroid
peroxidase (TpoAb) antibodies concentration was mea-
sured by radioimmunoassay, kit TpoAb RIA C.T. (BC
1018).
Thyroid dysfunction was assessed using TSH and F-T4
as well as routine use of thyroid hormones or antithyroid
medications. Cut-off levels for TSH were < 0.4 μIU/ml for
hyperthyroidism and > 4.0 μIU/ml for hypothyroidism.
Cut-off levels for free-T4 were < 0.8 ng/dl for hypothy-
roidism and > 1.9 ng/dl for hyperthyroidism. According
to both hormones, people in the sample were classified in
five categories: clinical hyperthyroidism (low serum TSH
combined with high levels of FT4), subclinical hyperthy-
roidism (low serum TSH with normal levels of F-T4),
euthyroidism (normal TSH and normal FT4), subclinical
hypothyroidism (high TSH with normal FT4) and clinical
hypothyroidism (high TSH combined with low levels of
FT4).
Assessment of dementia
Dementia was assessed using a harmonized one-phase
dementia diagnostic procedure by the 10/66 Dementia
Research Group and validated for use in population-
based studies in low and middle-income countries [11].
The diagnosis of dementia followed DSM-IV criteria [12].
The procedure includes assessment of cognitive function
with the Community Screening Instrument for Dementia
(CSI-D), [13] an adapted version of the Consortium to
Establish a Registry for Alzheimer's Disease (CERAD) ten
word list learning task with delayed recall and animal ver-Benseñor et al. BMC Public Health 2010, 10:298
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bal fluency, [14] a structured clinical mental state inter-
view with the Geriatric Mental State (GMS) [15,16], a
structured neurological assessment of localizing signs,
parkinsonism, ataxia, apraxia and primitive "release"
reflexes, assessment of participants' daily functioning and
general health with the CSI-D, and of functional and cog-
nitive decline with the History and Aetiology Schedule
Dementia Diagnosis and Subtype (HAS-DDS) [17]. An
algorithm combines data from all assessments and classi-
fies participants as cases of dementia or not, and by
dementia subtype (Alzheimer's disease, vascular demen-
tia, mixed and others) [10,11,18].
Age was classified in four age strata: 65-69, 70-74, 75-79
and ≥ 80 years-old. Education was classified as: no formal
education or one or more years of formal education.
Monthly income was classified as < US$ 127 or ≥ US$
127. Hypertension was defined if the participant had a
medical history of hypertension, used medication for
hypertension treatment or presented a systolic blood
pressure > 140 mm Hg and/or diastolic blood pressure >
90 mm Hg [19] Diabetes was defined if the participant
had a medical history of diabetes, used medication for
diabetes treatment or presented a fasting blood glucose ≥
126 mg/dl [20].
Data analysis
Data entry was carried out twice using the program EPI-
DATA 3.0, and the validity check was carried out to iden-
tify and correct data entry errors. Data was analyzed
using SPSS 15.0. Chi-square tests were used for compari-
son when appropriate. For continuous variables with nor-
mal distribution we used ANOVA. A logistic model was
used to assess the association of subclinical hyperthyroid-
ism with dementia, Alzheimer's disease and vascular
dementia crude, adjusted by age, with a multivariate
adjustment for age and BMI. TSH and free-thyroxine val-
ues were divided into five groups and a logistic model
adjusted for age was performed using the third quintile as
the reference. This was also performed for TSH and FT4
values within the normal range. Ninety-five percent con-
fidence intervals were provided. A P value less than 0.05
was considered statistically significant.
Results
Of the 1276 participants, 1086 presented normal thyroid
function, 33 subclinical hyperthyroidism and 157 sub-
clinical hypothyroidism (Figure 1). Mean (standard devia-
tion) TSH values for elderly people with subclinical
hyperthyroidism and subclinical hypothyroidism were
0.15 μIU/ml (0.12) with a range 0.0-0.3, and 6.6 μIU/ml
(3.4) with a range of 4.1-25.3, respectively; mean FT4
(standard deviation) for elderly people with subclinical
hyperthyroidism and subclinical hypothyroidism was
1.22 ng/dl (0.22) with a range of 0.89-1.67, and 0.96 ng/dl
(0.15) with a range of 0.8-1.8, respectively. There were 49
cases of dementia, including 19 (38.8%) cases of
Alzheimer's disease, 18 (36.7%) vascular, 9 (18.4%) mixed,
and 3 (6.1%) cases of all other causes of dementia.
Regarding the severity of dementia, 29 (59.2%) cases were
mild, 12 (24.5%) moderate, and 8 (16.3%) cases were
severe. Table 1 shows general characteristics of partici-
pants with and without dementia in elderly people with
subclinical hyperthyroidism and normal thyroid function.
Participants with dementia identified were older, leaner
and with a higher rate of high blood pressure compared
to people without dementia.
Table 2 shows the odds ratio of presence of any type of
dementia, Alzheimer's disease or vascular dementia
among people with subclinical hyperthyroidism using as
reference people with normal thyroid function. After
adjustment for age, we found an odds ratio (and 95% con-
fidence interval) of subclinical hyperthyroidism with any
type of dementia of 4.1 (95% CI, 1.3-13.1). We also found
a positive association between subclinical hyperthyroid-
ism and vascular dementia with an OR of 5.3 (1.1-26.4).
Both results persisted significant after age and BMI
adjustment. No association was found between subclini-
cal hyperthyroidism and Alzheimer's disease. Analyzing
data according to gender, after age-adjustment there was
a consistent positive relationship between subclinical
hyperthyroidism with dementia (OR, 8.0; 95% CI, 1.5-
43.4) and with Alzheimer's disease (OR, 12.4; 95% CI, 1.2-
128.4) in men. Both results persisted significant after age
and BMI adjustment. No women with subclinical hyper-
thyroidism present Alzheimer's disease in the sample. No
association was found between women with subclinical
hyperthyroidism with any type of dementia or vascular
dementia in the sample.
We also performed the same analysis on subjects with
subclinical hypothyroidism to determine whether there
was an association with dementia. However, in contrast
to the analysis for subclinical hyperthyroidism, we did not
find any positive results in our analysis of dementia with
subclinical hypothyroidism (data not showed).
We have also divided all TSH and FT4 values into five
groups. Using the third quintile as the reference, we
observed that subjects in the lowest quintile of TSH pre-
sented an age-adjusted OR for dementia of 3.6 (95% CI,
1.4-8.9) and an OR for vascular dementia of 9.3 (95% CI,
1.1-75.5). Restricting the analysis to only TSH values
within the normal range, and still using the third quintile
as the reference, we did not observe any significant asso-
ciation between TSH levels in quintiles and dementia.
The same analysis was performed for FT4, but we did not
observe any significant association, even when the analy-
sis was restricted to values within the normal range.Benseñor et al. BMC Public Health 2010, 10:298
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Discussion
In this cross-sectional study, we found a consistent asso-
ciation among older adults with subclinical hyperthyroid-
ism and any type of dementia and vascular dementia but
not with Alzheimer's disease. Analyzing presence of
dementia according to gender, after age and BMI adjust-
ment, subclinical hyperthyroidism was positively associ-
ated with any type of dementia and Alzheimer's disease in
men but not in women.
Most people with dementia live in low and middle
income countries but there is very sparse research data
about risk factors for dementia in these populations [18].
Although a study conducted in Nigeria showed a lower
prevalence of dementia than in developed countries
[21,22], studies carried out in Brazil [23,24], a middle
income country, have found the prevalence of dementia
to be similar to that found in Europe: 7.1% in an elderly
community-dwelling Brazilian population [23,24] and
5.1% in a community sample of elderly low-income peo-
ple using the 10/66 protocol [10,25].
One possible cause for dementia is iodine deficiency
[18,26]. In recent years, some studies described the levels
of serum TSH and FT4 in areas with borderline iodine
intake as a U-shaped curve with an increase in risk from
both low and high iodine intakes described in studies per-
formed in The Netherlands [27], Denmark [28], and
China [29]. Endemic goiter has been described in Brazil
since the 16th Century [30-33]. Since the early 1940's, salt
supplementation with iodine has been mandatory in
endemic areas, and only since 1997 has Brazil been con-







Age (years)* 78.5 (8.0) 71.9 (6.1) < 0.001
Proportion of women (%) 33 (67.3) 644 (60.2) 0.20
Race
White 13 (56.5) 530 (52.4) 0.81
Mixed 6 (26.1) 328 (32.4)
Black 4 (17.4) 154 (15.2)
Education (years)
No formal education 24 (50.0) 422 (39.6) 0.10
≥ 1 year of formal education 24 (50.0) 645 (60.4)
Monthly income
< 127 US$ 39 (79.6) 567 (53.0) < 0.001
≥ 127 US$ 10 (20.4) 503 (47.0)
BMI (kg/m2)* 22.1 (4.3) 25.8 (5.0) < 0.001
TSH (mU/l)* 1.4 (0.9) 1.7 (0.9) 0.04
Free-T4 (ng/dl)* 1.2 (1.2) 1.1 (0.4) 0.052
TPOAb positive antibodies (UI/ml)* 17.3 (12.9) 26.1 (81.5) 0.63
high blood pressure (%) † 42 (91.3) 822 (78.4) 0.02
diabetes (%)‡ 12 (26.1) 21.9 (224) 0.31
Total cholesterol (mg/dl) 203 (42) 210 (44) 0.29
HDL-cholesterol (mg/dl) 59 (18) 56 (15) 0.13
LDL-cholesterol (mg/dl) 116 (32) 125 (35) 0.09
Current smokers (%) 6 (23.1) 153 (24.6) 0.54
History of alcohol abuse (%) 11 (22.4) 225 (21.0) 0.46
*Mean (standard deviation).
†Diagnosis of high blood pressure was done if positive medical history of high blood pressure or treatment for high blood pressure or systolic 
blood pressure > 140 mm Hg or diastolic blood pressure > 90 mm Hg.
‡Diagnosis of diabetes if positive medical history of diabetes or treatment for diabetes or fasting blood glucose > 126 mg/dl.Benseñor et al. BMC Public Health 2010, 10:298
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sidered a country with adequate iodine supplementation.
Approximately 80.3% and 85.3% of women and men,
respectively, in this sample of subjects grew up in areas of
low iodine intake, and they have likely had adequate or
more than adequate iodine intake since 1996 [34-36].
This could explain the slightly higher frequency of sub-
clinical thyroid disease in this sample (3.0% in this sample
vs. 2.5% in a pooled-prevalence sample from several stud-
ies) [37], and presents a good opportunity to investigate
the relationship between dementia and subclinical thy-
roid function.
Our cross-sectional data showed an association of sub-
clinical hyperthyroidism with presence of dementia in
agreement with previous prospective studies [5-7,9].
However, in our analysis we found a positive relationship
of subclinical hyperthyroidism and any kind of dementia
and vascular dementia, in contrast to data from the Rot-
terdam Study [5] in which a positive association was
found for dementia and Alzheimer's disease; and from
the Framingham Study [9] in which a positive association
was found only for women in the lowest (< 1.0 mIU/l) and
in the highest tertile (> 2.1 mIU/l) of thyrothropin com-
pared to women in the middle tertile (respectively, RR,
2.39; 95% CI, 1.47-3.87 and RR 2.15; 95% CI, 1.31-3.52).
Further analysis of our data according to gender showed a
positive relationship among subclinical hyperthyroidism
and Alzheimer's disease only for men. We did not analyze
the association of subclinical hyperthyroidism and
Alzheimer's disease because no women in the sample
with a diagnosis of subclinical hyperthyroidism had
Alzheimer's disease. However, our results are also differ-
ent from the Framingham Heart Study in which no asso-
ciation was found between subclinical hyperthyroidism
and Alzheimer's disease in men [9].
Some specific characteristics of the population
included in the SPAH can help explain the high frequency
of vascular dementia. Cardiovascular disease is the first
cause of death in Brazil and the burden of stroke is very
high in the country, particularly in people with low socio-
economic status [38,39]. The number of cases of
Alzheimer's disease and vascular dementia in the present
study were similar, whereas in most studies carried out in
developed countries the prevalence of Alzheimer's dis-
ease is higher than the prevalence of other causes of
dementia [7,9,39]. However, recent research data have
also suggest that cardiovascular disease and Alzheimer's
disease overlap frequently [40-42].
We did not observe any evidence of a U-shaped rela-
tionship of TSH and FT4  values with dementia or
Alzheimer's disease. Restricting the analysis to TSH and
FT4 values within the normal range did not change the
results. After dividing TSH in groups, we only observe a
positive association with dementia for subjects in the
lowest quintile of TSH levels still using the third quintile
as the reference. These results differed from Tan et al that
found a U-shaped relationship between TSH levels within
the normal range and Alzheimer's disease in women [9];
and from Hogervorst et al that found an association of
subjects with high normal FT4 levels and an accelerated
cognitive decline and probably dementia at follow-up [8].
Our study has some weakness and strengths. It is a
cross-sectional study that can not bring information
about causality. We do not have precise information
about iodine intake along the life course, and the sample
size is restricted for some analyses according to dementia
subtypes. However, it is one of the first studies addressing
thyroid function and dementia in a very low-income pop-
ulation using a standardized protocol. Dementia diagno-
sis was done according to 10/66 protocol using adequate
instruments for the diagnosis of dementia in low and
middle income countries [16,18]. This implies some
degree of misclassification. However, the validation of
this method, which included a subsample from our cen-
ter, showed acceptable performance for its use in epide-
miological investigations. We did not analyze the possible
association of alterations in thyroid function and other
subtypes of dementia aside from Alzheimer's and vascu-
lar dementia as the number of cases was too small, as
would be expected in a population-based epidemiological
study. Prevalence of both subclinical hyper- and hypothy-
Figure 1 Participants of the São Paulo Ageing & Health Study in-
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roidism was also low. Thus, we cannot exclude chance
bias in the results. The number of subjects is also low for
an analysis according to dementia severity. Other
strength of the study was the exclusion of participants
using medicines for treatment of thyroid disorders.
Conclusion
In this low-income sample of elderly people, we found a
positive association of subclinical hyperthyroidism with
dementia, and specifically with vascular dementia. In
men, a positive association was found for dementia and
Alzheimer's disease. One possible explanation is the high
cardiovascular mortality in Brazil that could be associ-
ated with vascular dementia and possibly to Alzheimer's
disease.
Competing interests
Dr Bensenor, Dr Lotufo and Dr Menezes are recipients of a fellowship of Brazil-
ian Research Council (Conselho Nacional de Pesquisa - CNPq, Brasília, Brazil)
Authors' contributions
IJMB participated in the design, acquisition of data, analysis, and interpretation
of results, writing and revision of the manuscript. PAL participated in the
design, analysis, and interpretation of results, writing and revision of the manu-
script. PRM participated in the design and revision of the manuscript. MS par-
ticipated in the design, interpretation of results, writing and revision of the
manuscript. All authors read and approved the final version of the manuscript.
Acknowledgements
Declaration of Sources of Funding: Grant research: FAPESP, SP, Brazil and Wel-
come Trust, London, UK. They played no role in the design, execution, analysis 
and interpretation of data, or writing of the study. All authors are recipients of a 
scholarship from Conselho Nacional de Pesquisa, CNPq, Brasília, Brazil.
Author Details
1Hospital Universitário, University of Sao Paulo, Sao Paulo, Brazil, 2School of 
Medicine, University of Sao Paulo, Sao Paulo, Brazil, 3Hospital das Clínicas, 
University of Sao Paulo, Sao Paulo, Brazil and 4Hospital João Evangelista, São 
Paulo, Brazil
References
1. Gussekloo J, van Excel E, Craen AJ, Meinders AE, Frölich M, Westendorp 
RG: Thyroid status, disability and cognitive function, and survival in old 
age.  JAMA 2004, 292:2591-2599.
2. Volpato S, Guralnik JM, Fried LP, Remaley AT, Cappola AR, Launer LJ: 
Serum thyroxine level and cognitive decline in euthyroid older 
women.  Neurology 2002, 58:1055-61.
3. Ganguli M, Burmeister A, Seaberg EC, Belle S, DeKosky ST: Association 
between dementia and elevated tireotropic hormone (TSH): a 
community-based study.  Biol Psychiatry 1996, 40:714-725.
4. Kalmijn S, Mehta KM, Pols HA, Hofman A, Drexhage HA, Breteler MB: 
Subclinical hyperthyroidism and the risk of dementia. The Rotterdam 
Study.  Clin Endocrinol 2000, 53:733-737.
5. Wahlin A, Bunce D, Whalin TB: Longitudinal evidence of the impact of 
normal thyroid stimulating hormone variations on cognitive 
functioning in very old age.  Psychoneuroendocrinology 2005, 
30:625-637.
6. de Jong FJ, den Heijer T, Visser TJ, Rijke YB, Drexhage HA, Hofman A, 
Breteler MMB: Thyroid hormones, dementia, and atrophy of the medial 
temporal lobe.  J Clin Endocrinol Metab 2006, 91:2569-2573.
7. de Jong FJ, Masaki K, Remaley AT, Breteler MM, Petrovitch H, White LR, 
Launer LJ: Thyroid function, the risk of dementia and neuropathologic 
changes: The Honolulu-Asia Aging Study.  Neurobiol Aging 2007, 
30:600-606.
8. Hogervorst E, Huppert F, Matthews FE, Brayne C: Thyroid function and 
cognitive decline in the MRC Cognitive Function and Ageing Study.  
Psychoneuroendocrinology 2008, 33:1013-1022.
9. Tan ZS, Beiser A, Vasan RS, Au R, Auerbach S, Kiel DP, Wolf PA, Seshadri S: 
Thyroid function and the risk of Alzheimer Disease.  Arch Intern Med 
2008, 168:1514-1520.
10. Scazufca M, Menezes PR, Vallada HP, et al.: High prevalence of dementia 
among older adults from poor socio-economic background in São 
Paulo, Brazil.  Int Psychogeriat 2008, 20:394-405.
11. Prince M, Acosta D, Chiu H, Scazufca M, Varghese M: Dementia diagnosis 
in developing countries: a cross-cultural validation study.  Lancet 2003, 
361:909-917.
12. American Psychiatric Association: Diagnostic and Statistic Manual of 
Mental Disorders: DSM-IV Washington DC: Donnelley & Sons Company; 
1994. 
13. Hall KS, Hendric HH, Brittain HM, et al.: The development of a dementia 
screening interview in two distinct languages.  Int J Methods Psychiatr 
Res 1993, 361:909-917.
14. Welsh KA, Butters N, Mohs RC, Beekly D, Edland S, Fillenbaum G, Heyman 
A: The Consortium to Establish a Registry for Alzheimer's Disease 
(CERAD). Part V. A normative study of neuropsychological battery.  
Neurology 1994, 44:609-614.
15. Copeland JR, Dewey ME, Griffiths-Jones HM: A computerized psychiatric 
Diagnostic system and case nomenclature for elderly subjects: GMS 
and AGECAT.  Psychol Med 1986, 16:89-99.
16. Prince M, Acosta D, Chiu H, Scazufca M, Varghese M: Effects of education 
and culture on the validity of the Geriatric Mental State and its AGECAT 
algorithm.  Br J Psychiatry 2004, 185:429-436.
17. Dewey ME, Copeland JR: Diagnosis of dementia from the history and 
etiology schedule.  Int J Geriatr Psychiatry 2001, 16:912-917.
18. Prince M, Ferri CP, Acosta D, Alabanese E, Arizaga R, Dewey M, Gavrilova SI, 
Guerra M, Huang Y, Jacob KS, Krishnamoorthy ES, McKeigue P, Rodriguez 
JL, Salas A, Sosa AL, Sousa RM, Stewart R, Uwakwe R: The protocols for the 
10/66 dementia research group population-based research program.  
BMC Public Health 2007, 7:165.
19. The Seventh Report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)   
[http://www.nhlbi.nih.gov/guidelines/hypertension/]
20. American Diabetes Association: Diabetes Care 2006, 29(suppl 1):s43-s48.
21. Hendrie HC, Osuntokun BO, Hall KS, Ogunniyi AO, Hui SL, Unverzagt FW, 
Gureje O, Rodenberg CA, Baiyewu O, Musick BS: Prevalence of 
Alzheimer's disease and dementia in two communities: Nigerian 
African and African Americans.  Am J Psychiatry 1995, 152:1485-1492.
22. Hendrie HC, Ogunniyi AO, Hall KS, Baiyewu O, Unverzagt FW, Gureje O, 
Gao S, Evans RM, Ogunseyinde AO, Adeyinka AO, Musick B, Hui SL: 
Incidence of dementia and Alzheimer disease in 2 communities: 
Yoruba residing in Ibadan, Nigeria, and African Americans residing in 
Indianapolis, Indiana.  JAMA 2001, 285:739-747.
23. Herrera E Jr, Caramelli P, Silveira AS, Nitrini R: Epidemiologic survey of 
dementia in a community-dwelling Brazilian population.  Alzheimer Dis 
Assoc Disord 2002, 16:103-108.
24. Nitrini R, Caramelli P, Herrera E Jr, Bahia VS, Caixeta LF, Radanovic M, 
Anghinah R, Charchat-Fichman H, Porto CS, Carthery MT, Hartmann AP, 
Huang N, Smid J, Lima EP, Takada LT, Takahashi DY: Incidence of 
dementia in a community-dwelling Brazilian population.  Alzheimer Dis 
Assoc Disord 2004, 18:241-246.
25. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, 
Hasegawa , Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer 
E, Scazufca M, Alzheimer's Disease International: Global Prevalence of 
Dementia a Delphi consensus study.  Lancet 2005, 366:2112-2137.
26. Pretell EA, Delange F, Hostalek U, Corigliano S, Barreda L, Higa AM, 
Altschuller N, Barragan D, Cevallos JL, Gonzales O, Jara JA, Medeiros-Neto 
G, Montes JA, Muzzo S, Pacheco VM, Codero L: Iodine nutrition improves 
in Latin America.  Thyroid 2004, 14:590-599.
27. Hoogendoorn EH, Hermus AR, de Vegt F, Ross HA, Verbeek AL, Kiemeney 
LA, Swinkels DW, Sweep FC, den Heijer M: Thyroid function and 
prevalence of anti-thyroperoxidase antibodies in a population with 
borderline sufficient iodine intake: influences of age and sex.  Clin 
Chem 2006, 52:104-11.
Received: 21 December 2009 Accepted: 1 June 2010 
Published: 1 June 2010
This article is available from: http://www.biomedcentral.com/1471-2458/10/298 © 2010 Benseñor et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Public Health 2010, 10:298Benseñor et al. BMC Public Health 2010, 10:298
http://www.biomedcentral.com/1471-2458/10/298
Page 8 of 8
28. Carle A, Laurberg P, Pedersen IB, Knudsen N, Perrild H, Ovesen L, 
Rasmussen LB, Jorgensen T: Epidemiology of subtypes of 
hypothyroidism in Denmark.  Eur J Endocrinol 2006, 154:21-28.
29. Teng W, Shan Z, Teng X, Guan H, li Y, Teng D, Jin Y, Yu X, Fan C, Chong W, 
Yang F, Dai H, Yu Y, Li J, Chen Y, Zhao D, Shi X, Hu F, Mao J, Gu X, Yang R, 
Tong Y, Wang W, Gao T, Li C: Effect of iodine intake on thyroid diseases 
in China.  NEJM 2006, 354:2783-2793.
30. Freire-Maia DV: Sex and age prevalence of endemic epidemiological 
study.  J Hyg Epidemiol Microbiol Immunol 1981, 25:401-406.
31. Correa Filho HR, Vieira JB, Silva YS, Coelho GE, Cavalcante F dos A, Pereira 
M da P: Endemic goiter prevalence survey in Brazilian schoolchildren 6 
to 14 years old, 1994-1996.  Rev Panam Salud Publica 2002, 12:317-316.
32. Programa nacional de controle dos distúrbios por deficiência de iodo 
(PNCDDI-MS): Combate à deficiência de iodo no Brasil.   [http://
www.lats.org/idd/IODO.asp].
33. Batista Filho M, Rissin A: Nutritional transition in Brazil: geographic and 
temporal trends.  Cad Saúde Pública 2003, 19:181-191.
34. Duarte GC, Tomimori EK, Boriolli RA, Ferreira JE, Catarino RM, Camargo RY, 
Medeiros-Neto G: Echographic evaluation of the thyroid gland and 
urinary iodine concentration in school children from various regions in 
the state of São Paulo, Brazil.  Arq Bras Endocrinol Metabol 2005, 
48:842-848.
35. Marino MA, Martins LC, Esteves RZ, Kasamatsu TS, Maciel RM: A Urinary 
iodine in patients with auto-immune thyroid disorders in Santo André, 
SP, is comparable to normal controls and has been steady for the last 
10 years.  Arq Bras Endocrinol Metab 2009, 53:55-63.
36. de Pontes AA, Rocha AM, Leite DF, Lessa AF, Adan LF: Salt iodation in 
Brazil, a controversial subject.  Arq Bras Endocrinol Metab 2009, 
53:113-114.
37. Helfand M, Redfern CC: Screening for thyroid disease: an update. 
Clinical Guideline, Part 2.  Ann Intern Med 1998, 129:144-158.
38. Lotufo PA: Premature mortality from heart diseases in Brazil. A 
comparison with other countries.  Arq Bras Cardiol 1998, 70:321-325.
39. Lotufo PA, Bensenor IM: Stroke mortality in Brazil: one example of 
delayed epidemiological cardiovascular transition.  Int J Stroke 2009, 
4:40-41.
40. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, 
Persson G, Oden A, Svanborg A: 15-year longitudinal study of blood 
pressure and dementia.  Lancet 1996, 347:1141-1145.
41. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van Harskamp F, van 
Duijn CN, Van Broeckhoven C, Grobbee DE: Atherosclerosis, 
apolipoprotein E, and prevalence of dementia and Alzheimer's disease 
in the Rotterdam Study.  Lancet 1997, 349:151-154.
42. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, 
Soininen H, Tuomilehto J, Nissinen A: Midlife vascular risk factors and 
Alzheimer's disease in later life: longitudinal, population based study.  
BMJ 2001, 322:1447-1451.
43. Gandra YR: O bócio endêmico no Estado de São Paulo.  Arquivos de 
Hygiene e Saúde Pública de São Paulo 1966, 20:167-181. in Portuguese
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2458/10/298/prepub
doi: 10.1186/1471-2458-10-298
Cite this article as: Benseñor et al., Subclinical hyperthyroidism and demen-
tia: the Sao Paulo Ageing & Health Study (SPAH) BMC Public Health 2010, 
10:298